Research recommendation(s) from an individual piece of guidance
- Guidance:
- Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment
- Date issued:
Research recommendations coming out of this guidance
- NICE recommends further research to validate the accuracy and precision of the My5-FU assay for the quantitative determination of 5-fluorouracil (5-FU) at the lower end of its measuring range with analytical reference standard methods, including high-performance liquid chromatography and liquid chromatography-mass spectrometry.
- NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic dose adjustment of continuous infusion 5-FU in people with colorectal cancer.
- NICE recommends further research to establish optimal target dose ranges for 5-FU plasma levels in people with head and neck cancer, stomach cancer and pancreatic cancer.
- NICE recommended further research to explore the impact of having experiences of patients having continuous infusion 5-FU and take into account the impact on quality of life. The potential consequences of introducing pharmacokinetic dose adjustment should also be explored.